Kymab names Groendahl CEO, Chiswell as chair
This article was originally published in Scrip
Executive Summary
Biopharmaceutical firm Kymab, which develops fully human monoclonal antibodies, has named Dr Christian Groendahl and Dr David Chiswell chief executive officer and chair of the board, respectively. Dr Groendahl joins the Cambridge, UK-based firm from Zealand Pharma where he was chief scientific officer. Meanwhile Dr Chiswell has previously been chair of a number of biotechnology companies – including Nabriva Therapeutics, Sosei, and Daniolabs – and is currently non-executive chair of Albireo Pharma and a director of Nabriva Therapeutics. He joined the Kymab board in 2012. Both appointments are effective from 16 September 2013.